{"id":"tamoxifen-oral-tablet","safety":{"commonSideEffects":[{"rate":"25-40","effect":"Hot flashes"},{"rate":"20-30","effect":"Vaginal discharge"},{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Vaginal bleeding"},{"rate":"1-3","effect":"Thromboembolic events"},{"rate":"0.5-1","effect":"Endometrial cancer"},{"rate":"1-2","effect":"Cataracts"}]},"_chembl":{"chemblId":"CHEMBL83","moleculeType":"Small molecule","molecularWeight":"371.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tamoxifen competitively binds to estrogen receptors on hormone-responsive breast cancer cells, preventing endogenous estrogen from activating these receptors and promoting cell proliferation. This leads to cell cycle arrest and apoptosis in estrogen receptor-positive tumors. It also has partial agonist activity in some tissues, which accounts for its effects on bone and lipid metabolism.","oneSentence":"Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen binding to its receptor on breast cancer cells, inhibiting their growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:57.958Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer (adjuvant and metastatic)"},{"name":"Breast cancer risk reduction in high-risk women"},{"name":"Ductal carcinoma in situ (DCIS)"}]},"trialDetails":[{"nctId":"NCT06492616","phase":"PHASE3","title":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2024-09-27","conditions":"Breast Cancer","enrollment":4220},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT05101564","phase":"PHASE2","title":"Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer","status":"COMPLETED","sponsor":"Jennifer Lee Caswell-Jin","startDate":"2023-03-20","conditions":"Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer","enrollment":19},{"nctId":"NCT06917313","phase":"PHASE2","title":"FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-05","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":92},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05645536","phase":"PHASE3","title":"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study","status":"ENROLLING_BY_INVITATION","sponsor":"Tolmar Inc.","startDate":"2022-12-28","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT06369285","phase":"PHASE2","title":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Puma Biotechnology, Inc.","startDate":"2024-11-19","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":150},{"nctId":"NCT05128773","phase":"PHASE3","title":"Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity","status":"TERMINATED","sponsor":"Sanofi","startDate":"2022-02-17","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT04300790","phase":"PHASE2","title":"Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-23","conditions":"Breast Cancer","enrollment":69},{"nctId":"NCT03161353","phase":"PHASE2","title":"Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2017-06-26","conditions":"Breast Cancer","enrollment":377},{"nctId":"NCT03820830","phase":"PHASE3","title":"Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-08-27","conditions":"Breast Cancer Recurrent","enrollment":405},{"nctId":"NCT03346200","phase":"PHASE2","title":"Low Dose Tamoxifen for Mammographic Density Reduction","status":"COMPLETED","sponsor":"Per Hall","startDate":"2016-11","conditions":"Risk Reduction, Mammographic Density Reduction","enrollment":1440},{"nctId":"NCT04985266","phase":"PHASE2","title":"A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2022-03-30","conditions":"ER+ Breast Cancer, HER2-negative Breast Cancer","enrollment":1100},{"nctId":"NCT03528902","phase":"PHASE2","title":"Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-10-01","conditions":"Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension","enrollment":18},{"nctId":"NCT04915846","phase":"PHASE1, PHASE2","title":"Tamoxifen Therapy for Myotubular Myopathy","status":"TERMINATED","sponsor":"James Dowling","startDate":"2020-12-18","conditions":"X Linked Myotubular Myopathy","enrollment":6},{"nctId":"NCT02188745","phase":"PHASE2","title":"ER Reactivation Therapy for Breast Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-03-11","conditions":"Metastatic Breast Cancer","enrollment":19},{"nctId":"NCT03229499","phase":"PHASE2","title":"Pulmonary Hypertension and Anastrozole Trial","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-12-07","conditions":"Pulmonary Arterial Hypertension","enrollment":84},{"nctId":"NCT00382070","phase":"PHASE3","title":"Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NSABP Foundation Inc","startDate":"2006-08","conditions":"Breast Cancer","enrollment":3966},{"nctId":"NCT02278120","phase":"PHASE3","title":"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-20","conditions":"Advanced Metastatic Breast Cancer","enrollment":672},{"nctId":"NCT01481883","phase":"PHASE4","title":"Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?","status":"COMPLETED","sponsor":"The Alfred","startDate":"2012-01","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":13},{"nctId":"NCT00106691","phase":"PHASE3","title":"Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)","status":"COMPLETED","sponsor":"GTx","startDate":"2005-01","conditions":"Preneoplastic Conditions, Prostatic Intraepithelial Neoplasia","enrollment":1589},{"nctId":"NCT05890287","phase":"NA","title":"A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-16","conditions":"HR Positive HER2 Negative Advanced Breast Cancer","enrollment":60},{"nctId":"NCT05110170","phase":"PHASE3","title":"Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2020-10-15","conditions":"Breast Cancer","enrollment":188},{"nctId":"NCT04433494","phase":"PHASE1","title":"A Study of TY-302 in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"TYK Medicines, Inc","startDate":"2020-12-07","conditions":"Breast Cancer, Solid Tumor","enrollment":60},{"nctId":"NCT04933240","phase":"PHASE4","title":"Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot Trial","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2022-05","conditions":"Vaginal Bleeding","enrollment":""},{"nctId":"NCT04666961","phase":"PHASE2","title":"Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ","status":"RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2021-02-03","conditions":"Ductal Carcinoma in Situ, Extensive Disease, Mastectomy","enrollment":262},{"nctId":"NCT02586675","phase":"PHASE1","title":"TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-02-23","conditions":"Breast Cancer, Breast Cancer - Female, Breast Cancer - Male","enrollment":7},{"nctId":"NCT02982083","phase":"NA","title":"Clinical Trial on the Efficacy of Raloxifene on Disease Activity in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sara Saeidi Shahri","startDate":"2015-09","conditions":"Rheumatoid Arthritis","enrollment":34},{"nctId":"NCT03078751","phase":"PHASE2","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-20","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT03043820","phase":"PHASE3","title":"Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder","status":"COMPLETED","sponsor":"Iris Sommer","startDate":"2016-08","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":110},{"nctId":"NCT04852081","phase":"","title":"Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2021-01-01","conditions":"Breast Cancer Stage IV","enrollment":1000},{"nctId":"NCT04666805","phase":"","title":"Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast","status":"UNKNOWN","sponsor":"First Hospital of China Medical University","startDate":"2020-07-01","conditions":"Breast Cancer","enrollment":1354},{"nctId":"NCT04116827","phase":"","title":"Sleep and Activity Patterns in Pre-menopausal Breast Cancer Patients on Tamoxifen Using a Wrist-worn Internet of Things Device","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2018-08-10","conditions":"Sleep Disorder, Breast Cancer","enrollment":20},{"nctId":"NCT03764462","phase":"PHASE1","title":"Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2018-12-14","conditions":"Osteoporosis","enrollment":52},{"nctId":"NCT03824171","phase":"PHASE1","title":"Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2019-02-28","conditions":"Osteoporosis","enrollment":52},{"nctId":"NCT03997539","phase":"PHASE2","title":"A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-08-15","conditions":"Metastatic Breast Cancer","enrollment":256},{"nctId":"NCT02824224","phase":"PHASE4","title":"Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2016-09-06","conditions":"Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices","enrollment":42},{"nctId":"NCT03844685","phase":"PHASE2","title":"Red Clover and Lifestyle Changes to Contrast Menopausal Symptoms in Premenopausal Breast Cancer Patients Given Tamoxifen","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2012-07-05","conditions":"Breast Cancer","enrollment":88},{"nctId":"NCT01073865","phase":"PHASE3","title":"Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-02-26","conditions":"Breast Cancer","enrollment":222},{"nctId":"NCT00723398","phase":"NA","title":"Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2009-03","conditions":"Breast Cancer","enrollment":266},{"nctId":"NCT02513849","phase":"PHASE1","title":"Tamoxifen in Patients With Oesophageal Cancer","status":"UNKNOWN","sponsor":"University of Nottingham","startDate":"2015-12","conditions":"Cancer, Gastrointestinal Neoplasms","enrollment":20},{"nctId":"NCT02467686","phase":"PHASE4","title":"Breast Cancer, Sexuality and Black Cohosh","status":"UNKNOWN","sponsor":"Irmandade da Santa Casa de Misericordia de Sao Paulo","startDate":"2014-01","conditions":"Sexuality","enrollment":60},{"nctId":"NCT00171704","phase":"PHASE3","title":"A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-04","conditions":"Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women","enrollment":263},{"nctId":"NCT00030147","phase":"PHASE4","title":"Raloxifene and Rimostil for Perimenopause-Related Depression","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2002-02","conditions":"Perimenopausal Depression, Depression","enrollment":65},{"nctId":"NCT02479256","phase":"PHASE4","title":"Clomiphene Citrate Versus Tamoxifen for Ovulation Induction in PCOs","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2015-06","conditions":"PCOS","enrollment":600},{"nctId":"NCT02690870","phase":"PHASE4","title":"Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2017-01","conditions":"Infertility","enrollment":210},{"nctId":"NCT01821066","phase":"PHASE1","title":"A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Healthy","enrollment":25},{"nctId":"NCT00774267","phase":"","title":"Study Evaluating Changes In Mammographic Breast Density","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Osteoporosis","enrollment":507},{"nctId":"NCT00241449","phase":"PHASE3","title":"A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"1998-11","conditions":"Breast Cancer, Metastasis","enrollment":51},{"nctId":"NCT00437359","phase":"PHASE2","title":"Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer","status":"TERMINATED","sponsor":"Japan Breast Cancer Research Network","startDate":"2007-05","conditions":"Breast Neoplasms","enrollment":240},{"nctId":"NCT00637871","phase":"PHASE2","title":"Casodex - Nolvadex Combination","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-11","conditions":"Gynaecomastia, Prostate Cancer","enrollment":""},{"nctId":"NCT00847821","phase":"","title":"Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-05","conditions":"Postmenopause","enrollment":185},{"nctId":"NCT01050634","phase":"","title":"Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-11","conditions":"Post Menopausal Women With Early Breast Cancer","enrollment":980},{"nctId":"NCT00383422","phase":"PHASE3","title":"Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-10","conditions":"Osteoporosis, Postmenopausal","enrollment":320},{"nctId":"NCT00649090","phase":"PHASE4","title":"A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-03","conditions":"Breast Neoplasms","enrollment":1549}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tamoxifen Oral Tablet","genericName":"Tamoxifen Oral Tablet","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen binding to its receptor on breast cancer cells, inhibiting their growth. Used for Hormone receptor-positive breast cancer (adjuvant and metastatic), Breast cancer risk reduction in high-risk women, Ductal carcinoma in situ (DCIS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}